GlobalData has released its new
Country report, PharmaPoint: Epilepsy - India Drug Forecast and Market Analysis
to 2022. Epilepsy is a brain disorder characterized by spontaneously occurring
and recurrent seizures. The market is heavily driven by the sales of
antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is
currently dominated by UCBs Keppra and GlaxoSmithKlines Lamictal.
Although both drugs have experienced
significant generic erosion, they form the mainstay of epilepsy treatment in
the nine markets and will continue to have significant market share during the
forecast period. Other key drugs include older generation AEDs such as Pfizers
Dilantin, Abbotts Depakote, and Novartis Tegretol and Trileptal which still
have significant usage due to their longevity in the market. However, the AED
dominance landscape will continue to shift towards newer generation drugs
particularly following the recent market entry of GlaxoSmithKlines
Trobalt/Potiga and Eisais Fycompa which both offer first-in-class mechanisms of
action.
To
Read the Complete Report with TOC Visit:
http://www.marketresearchreports.biz/analysis-details/pharmapoint-epilepsy-india-drug-forecast-and-market-analysis-to-2022
Given Indias large population of epilepsy patients, the AED market is fairly large, despite the relatively low cost of treatment. The main driver for growth in this market will be the continued uptake of recent AEDs, a growing middle class with better healthcare access, and increased epilepsy treatment in the whole population. However, loose government regulation of patent protection severely impacts brand drug profitability in India.
Scope
- Overview of Epilepsy including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in India including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in India from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting India Epilesy market.
To Buy The Copy of This Report Visit: http://www.marketresearchreports.biz/analysis/163781
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Epilepsy
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in India
About Us
MarketResearchReports.Biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are especially designed to save time and money of our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948
Email: sales@marketresearchreports.biz
Website: http://www.marketresearchreports.biz/
No comments:
Post a Comment